The ADC drug "Dabigatran Etexilate" from Daiichi Sankyo/Astrazeneca PLC Sponsored ADR (AZN.US) has received approval for another new indication in China.
On August 12, Daiichi Sankyo announced that a new indication for its blockbuster ADC drug "Enhertu," developed in collaboration with AstraZeneca, has been approved for marketing.
On August 12, Daiichi Sankyo announced that a new indication for its blockbuster ADC drug "trastuzumab deruxtecan" developed in collaboration with AstraZeneca has been approved for launch. The indication is for use in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
Trastuzumab deruxtecan (DS-8201, brand name: Enhertu) is a HER2-targeting ADC drug developed by Daiichi Sankyo, in collaboration with AstraZeneca for global development and commercialization. The drug consists of a HER2-targeting antibody, a cleavable tetrapeptide linker, and a topoisomerase I inhibitor DXd (derivative of irinotecan), with a DAR of approximately 8.
Related Articles
UNISOUND (09678) has released its self-developed multimodal medical imaging model "U2-RadiMed".
Revenue far exceeded market expectations, and quarterly losses continued to narrow. Has WeRide (0800.HK, WRD.US) finally turned a corner?
"NVIDIA Corporation challenger" Cerebras (CBRS.US) reported Q2 results that fell short of expectations, with hardware revenue plummeting 23%, and the stock price dropped 16% in after-hours trading.
UNISOUND (09678) has released its self-developed multimodal medical imaging model "U2-RadiMed".
Revenue far exceeded market expectations, and quarterly losses continued to narrow. Has WeRide (0800.HK, WRD.US) finally turned a corner?
"NVIDIA Corporation challenger" Cerebras (CBRS.US) reported Q2 results that fell short of expectations, with hardware revenue plummeting 23%, and the stock price dropped 16% in after-hours trading.
RECOMMEND
